Pharmaceutical composition for preventing or treating cancer comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients

A combination of a Salmonella strain and an immune checkpoint inhibitor targets cancer cells effectively, addressing the limitations of current treatments by significantly suppressing tumor growth and improving survival rates in resistant cancers.

JP2024540738APending Publication Date: 2024-11-01CNCURE BIOTECH INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2024526737
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-05
Filing Date
2022-11-04
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Existing cancer treatments, particularly those using immune checkpoint inhibitors, have limited efficacy, with less than 30% response rate and no effective methods for resistant cancers, necessitating a more reliable composition for prevention and treatment.

Method used

A pharmaceutical composition combining a Salmonella strain and an immune checkpoint inhibitor, specifically targeting PD-L1, to selectively act on cancer cells, enhancing treatment efficacy.

Benefits of technology

Significantly suppresses tumor growth and improves survival rates in cancers resistant to single therapies, offering a fundamental and efficient treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024540738000001_ABST
    Figure 2024540738000001_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients. The present invention can be useful as a prophylactic or therapeutic composition for cancer, particularly for cancers that are resistant or difficult to treat with a single anticancer therapy, by administering the bacteria in combination with an immune checkpoint inhibitor to significantly suppress tumor size and improve survival rates.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a pharmaceutical composition for preventing or treating cancer, which comprises a Salmonella strain and an immune checkpoint inhibitor as active ingredients. [Background technology]

[0002] Advances in immunology have led to the development of immune checkpoint inhibitors, ushering in a new era of cancer treatment. However, the patients who respond effectively to immune checkpoint inhibitors vary by cancer type, and the efficacy is less than 30%. Therefore, many studies are being conducted to improve the therapeutic effect of immune checkpoint inhibitors. Among them, bacteria have attracted great interest as a therapeutic agent. Although bacteria alone may not be a complete treatment, research is being conducted to improve the therapeutic effect by changing bacteria into anticancer drugs, antitumor genes, or immunogenic antigens alone or in combination.

[0003] When cancer develops in an individual, angiogenesis and cell growth proceed at a very fast rate in the body, and an environment with incomplete angiogenesis and lack of oxygen is created inside the cancer tissue, which can be very suitable for the proliferation of anaerobic bacteria such as Salmonella or E. coli. Therefore, currently, cancer treatment using bacteria capable of targeting cancer, such as Salmonella and Clostridium, targets solid tumors and relies on the function of specific bacteria that can proliferate within the tumor, but when an oncolytic protein or reporter protein is introduced into the bacteria and the transformed bacteria is administered to an individual, it is possible to specifically identify cancer tissues and minimize side effects that are toxic to normal cells, thereby treating cancer.

[0004] Therefore, the present invention has been made to solve the problem of developing a preventive or therapeutic agent for solid cancer, and relates to a pharmaceutical composition for preventing or treating cancer, comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients. The pharmaceutical composition of the present invention is expected to be widely used in the field of cancer treatment, since it has the effect of improving survival rate in an in vivo system. Summary of the Invention [Problem to be solved by the invention]

[0005] The present inventors have made intensive research efforts to find a reliable composition for preventing and treating cancers that are difficult to treat with resistance and single anticancer therapy and have no effective treatment methods. As a result, it was confirmed that tumor growth was significantly suppressed and improved by combination therapy of a Salmonella strain that selectively acts on cancer and an immune checkpoint inhibitor including PD-L1. As a result, the present invention was completed by finding a novel and effective method and composition for treating cancer.

[0006] Therefore, an object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients.

[0007] Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, the claims and the drawings.

[0008] However, the technical problems that the present invention aims to solve are not limited to those mentioned above, and other problems not mentioned will be clearly understood by those having ordinary skill in the art from the following description. [Means for solving the problem]

[0009] Various embodiments described herein will now be described with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and steps, are described in order to provide a thorough understanding of the present invention. However, a particular embodiment can be practiced without one or more of these specific details, or with other known methods and configurations. In other instances, known processes and manufacturing techniques are not described in specific detail in order to avoid unnecessarily obscuring the present invention. References throughout this specification to "one embodiment" or "embodiment" mean that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the phrases "in one embodiment" or "embodiment" appearing in various locations throughout this specification do not necessarily refer to the same embodiment of the present invention. Additionally, particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.

[0010] Unless otherwise defined in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0011] Throughout the specification, when a part "comprises" a certain element, this means that it can further include other elements, but not to the exclusion of other elements, unless otherwise specified.

[0012] According to one aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating cancer, comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients.

[0013] The present inventors have made intensive research efforts to find a reliable composition for preventing and treating cancers that are difficult to treat with resistance and single anticancer therapy and have no effective treatment methods. As a result, it was confirmed that tumor growth was significantly suppressed and improved by combination therapy of a Salmonella strain that selectively acts on cancer and an immune checkpoint inhibitor including PD-L1. As a result, the present invention was completed by finding a novel and effective method and composition for treating cancer.

[0014] In this specification, the term "Salmonella" refers to a type of Proteobacteria belonging to the genus Salmonella, which is an enterobacteria. It is a rod-shaped bacterium with a diameter of about 0.7 to 1.5 μm and a length of about 2 to 5 μm, and mainly lives in the digestive tract of humans and animals.

[0015] As used herein, the term "immune checkpoint" refers to an intracellular signaling system that maintains self-tolerance and protects tissues from excessive immune responses that cause damage. Immune checkpoint proteins are cell membrane proteins that regulate immune checkpoints and can inhibit the differentiation, proliferation, and activity of immune cells. Specifically, they are expressed in activated T cells to reduce T cell proliferation, cytokine secretion, and cytotoxicity, thereby inhibiting excessive T cell activity. Some immune checkpoints act as one of the main mechanisms by which tumor cells evade a patient's immune response. Thus, the term "a composition for immune checkpoint inhibition" or "immune checkpoint inhibitor" is a form of cancer immunotherapy that uses the body's immune system to selectively attack cancer cells. An anti-cancer component or anti-cancer adjuvant component that enhances T cell activity and promotes anti-tumor immune responses by blocking the expression or activity of immune checkpoint proteins. means.

[0016] In this specification, the term "cancer" refers to a disease characterized by uncontrolled cell growth, which forms a mass of cells called a tumor and infiltrates the surrounding tissues, and in severe cases, metastasizes to other organs in the body. It is also called a neoplasm academically. Cancer is an intractable chronic disease that cannot be fundamentally cured even with surgery, radiation, and chemotherapy, and causes pain to patients and ultimately leads to death. There are various factors that cause cancer, which are classified into internal and external factors. Although the exact mechanism by which normal cells are transformed into cancer cells has not been elucidated, it is known that a considerable number of cancers are caused by external factors such as environmental factors. Internal factors include genetic factors and immunological factors, and external factors include chemicals, radiation, and viruses. Genes related to the development of cancer include oncogenes and tumor suppressor genes, and cancer occurs when the balance between these is disturbed by the internal or external factors described above. In the present invention, the targets of prevention, improvement or treatment may be melanoma, fallopian tube cancer, brain cancer, small intestine cancer, esophageal cancer, lymphatic gland cancer, gallbladder cancer, blood cancer, thyroid cancer, endocrine gland cancer, oral cancer, liver cancer, biliary tract cancer, colon cancer, rectal cancer, cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenal cancer, prostate cancer, breast cancer, brain tumor, lung cancer, anaplastic thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureter cancer, pancreatic cancer, bone / soft tissue sarcoma, skin cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia and solitary myeloma, but are not limited thereto.

[0017] As used herein, the term "prevention" refers to inhibiting the occurrence of a disease or condition in a subject who has not been diagnosed as having the disease or condition but is susceptible to such disease or condition.

[0018] As used herein, the term "treatment" refers to any action using the active ingredient of the present invention to improve symptoms caused by cancer or to benefit an individual, and refers to an attempt to obtain a useful or desirable result, including a clinical result. A useful or desirable clinical result may include, but is not necessarily limited to, alleviation or improvement of one or more symptoms or conditions, reduction in the extent of disease, stabilization of the disease state, inhibition of disease occurrence, inhibition of disease spread, delay or prolongation of disease progression, delay or prolongation of disease onset, improvement or alleviation, and attenuation (partial or total) of the disease state, whether detectable or not. Also, "treatment" may refer to the prolongation of a patient's survival beyond that expected in the absence of treatment. Furthermore, "treatment" may refer to the inhibition of disease progression, temporary prolongation of disease progression, and more preferably, to the permanent halting of disease progression. As will be understood by those skilled in the art, if the treatment produces the opposite result in the patient to whom the treatment is administered while improving a particular disease state, i.e., a result that is greater than any benefit that is affected by the treatment, the result may not be beneficial or desirable.

[0019] Therefore, the composition of the present invention may be a composition for treating these diseases by itself, or may be administered together with other anticancer drugs and applied as a therapeutic adjunct to the diseases. Therefore, in this specification, the term "treatment" or "therapeutic agent" includes the meaning of "therapeutic adjunct" or "therapeutic adjunct".

[0020] In the present specification, the term "pharmaceutical composition" is not limited to these, but can be formulated into oral dosage forms such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injection solutions by a conventional method. The pharmaceutical composition of the present invention can contain a pharmaceutical acceptable carrier. The pharmaceutical acceptable carrier can be administered orally, orally, or in the form of a pharmaceutical composition that is administered ... For oral administration, binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, dyes, flavors, etc. may be used, and for injections, buffers, preservatives, soothing agents, solubilizers, isotonic agents, stabilizers, etc. may be mixed and used, and for topical administration, bases, excipients, lubricants, preservatives, etc. may be used. The pharmaceutical composition of the present invention may be prepared in various forms by mixing with the above-mentioned pharma- ceutical acceptable carriers. For example, for oral administration, it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injections, it may be prepared in the form of unit-dose ampoules or multiple-dose forms. It may also be prepared in the form of solutions, suspensions, tablets, capsules, sustained-release preparations, etc. On the other hand, examples of carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil, etc. In addition, fillers, anti-agglomerating agents, lubricants, wetting agents, flavors, emulsifiers, preservatives, etc. may be additionally included.

[0021] In the present specification, the term "administration" or "administering" means to directly administer a therapeutically effective amount of the composition of the present invention to a subject so that the same amount is formed in the body of the subject, including introducing the composition of the present invention into a patient by any suitable method, and the administration route of the composition of the present invention may be administered through any common route as long as it can reach the target tissue. The administration route may be oral, intraperitoneal, intravenous, intramuscular, subcutaneous, intradermal, intranasal, intrapulmonary, rectal, intracavitary, intraperitoneal, or intradural, but is not limited thereto. In the present invention, the effective amount can be adjusted depending on various factors including the type of disease, the severity of the disease, the type and content of the active ingredient and other ingredients contained in the composition, the type of dosage form, and the patient's age, weight, general health condition, sex, and diet, administration time, administration route, and secretion rate of the composition, treatment period, and drugs used simultaneously. For adults, the therapeutic pharmaceutical composition can be administered in an amount of 50ml to 500ml per dose, and in the case of a compound, the dosage is 0.1ng / kg to 10mg / kg, and in the case of a monoclonal antibody, the dosage is 0.1ng / kg to 10mg / kg. The administration interval may be 1 to 12 times a day, and when administered 12 times a day, it can be administered once every 2 hours. In addition, the pharmaceutical composition of the present invention can be administered alone or in combination with other therapies known in the art, such as chemotherapy, radiation, and surgery, for the treatment of the target cancer. Additionally, the pharmaceutical compositions of the present invention can be administered in admixture with other therapies designed to enhance immune responses, such as adjuvants or cytokines (or nucleic acids encoding cytokines) as are well known in the art. Other standard delivery methods may also be used, such as biolistic delivery or ex vivo treatments. In ex vivo treatments, for example, antigen presenting cells (APCs), dendritic cells, peripheral blood mononuclear cells, or bone marrow cells are obtained from the patient or a suitable donor and activated ex vivo with the pharmaceutical composition and then administered to the patient.

[0022] In the present invention, the term "therapeutically effective amount" means the content of the composition in an amount sufficient to provide a therapeutic or prophylactic effect to an individual to whom the pharmaceutical composition of the present invention is to be administered, and thus includes a "prophylactically effective amount."

[0023] According to a specific embodiment of the invention, the compositions are administered in combination.

[0024] According to a specific embodiment of the present invention, the Salmonella strain is selected from the group consisting of Salmonella typhimurium, Salmonella choleraesuis, Salmonella enteritidis, and the like. Salmonella enteritidis, Salmonella dublin, Salmonella typhi The Salmonella strain may be selected from the group consisting of Salmonella typhisuis, Salmonella derby, and Salmonella gallinarum. Specifically, the Salmonella strain may be, but is not limited to, Salmonella typhimurium.

[0025] In the present invention, the term "Salmonella enterica" ​​refers to a bacterium of the Enterobacteriaceae family that inhabits the intestinal tract of primates, including humans, and secretes cytolysin, which is known as an exotoxin. Cytolysin is a cytotoxic protein with a molecular weight of about 34 kDa, and is known to have a hemolytic effect that destroys red blood cells in the intestines of primates, including humans, and to induce cell lysis by forming pores in the membranes of normal cells, leading to severe vascular inflammation and local tissue necrosis, which can even lead to death. However, recent research results have shown that cytolysin isolated and purified from Salmonella enterica specifically reacts with cancer tissues present in the intestinal tract of the body to induce the death of cancer tissues, and is therefore attracting attention as a next-generation anti-cancer therapeutic agent. Therefore, bacteria transformed with a gene that secretes cytolysin, a cytotoxic substance, have a high possibility of being used as an anti-cancer therapeutic agent targeting cancer tissues.

[0026] According to the present invention, the host cell includes cells of mammalian, plant, insect, fungal or cellular origin, for example, bacterial cells such as E. coli, Streptomyces or Salmonella strains, yeast cells, fungal cells such as Pichia pastoris; insect cells such as Drosophila, Spodoptera Sf9 cells, animal cells such as CHO (Chinese hamster ovary cells), SP2 / 0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), 293T cells, Bowes melanoma cells, HT-1080 cells, BHK cells (Baby Hamster Kidney cells), HEK cells (Human Embryonic Kidney cells) or PERC.6 cells (human retinal cells), and at least one selected from the group consisting of plant cells, but is not limited thereto. For the purposes of the present invention, the strain may be an anaerobic strain, for example, at least one selected from the group consisting of Salmonella, Clostridium, Bifidobacterium and Escherichia coli, preferably at least one selected from the group consisting of Salmonella typhimurium, Salmonella choleraesuis and Salmonella enteritidis, more preferably, but not limited to, Salmonella typhimurium.

[0027] The strain of the present invention may be attenuated.

[0028] The "attenuation" of the present invention means that a gene or the like is modified to reduce toxicity and other side effects when the microorganism is administered to a patient. For the purposes of the present invention, when the strain is a Salmonella strain, the following are modified for attenuation: aroA, aroC, aroD, aroE, Rpur, htrA, ompR, ompF, ompC, galE, cya, crp, cyp, phoP, phoQ, rfaY, dksA, hupA, sipC, clpB, clpP, clpX, pab, nadA, pncB, pmi, rpsL, hemA, rfc, poxA, galU, cdt, pur, ssa, guaA, guaB The gene of the present invention may be modified in at least one gene selected from the group consisting of, but not limited to, fliD, flgK, flgL, relA, and spoA. The method of modifying the gene of the present invention can be performed by various gene deletion or disruption methods known in the art, for example, the deletion and disruption methods can be performed by methods such as homologous recombination, chemical mutagenesis, irradiation mutagenesis, or transposon mutagenesis.

[0029] In the present invention, the strain targets the inside of cancer tissue, which is an oxygen-deficient environment with incomplete angiogenesis that is very suitable for the proliferation of anaerobic strains. Therefore, when a recombinant vector capable of simultaneously expressing a reporter protein that can be imaged in real time and an anti-cancer protein in a balanced manner is introduced into such a strain, cancer can be diagnosed and treated at the same time very effectively.

[0030] According to a specific embodiment of the invention, the immune checkpoint inhibitor is selected from the group consisting of Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), Programmed cell death protein 1 (PD-1), Programmed death-ligand 1 (PD-L1), KIR, LAG3, CD137, OX40, CD47, CD276, CD27, and GITR.

[0031] Specifically, the immune checkpoint inhibitor is Programmed Death-Ligand 1 (PD-L1).

[0032] In the present invention, the term "Programmed death-ligand 1 (PD-L1)" refers to a protein present on the surface of cancer cells and hematopoietic cells. Also known as CD274 and B7-H1, PD-L1 and PD-L2, proteins present on the surface of cancer cells, bind to PD-1, a protein present on the surface of T cells, preventing the T cells from attacking the cancer cells. Anticancer immunotherapy binds to the PD-1 receptor of T cells and inhibits the evasive function of cancer cells.

[0033] According to specific embodiments of the invention, the cancer is selected from the group consisting of melanoma, fallopian tube cancer, brain cancer, small intestine cancer, esophageal cancer, lymphatic gland cancer, gallbladder cancer, blood cancer, thyroid cancer, endocrine gland cancer, oral cavity cancer, liver cancer, biliary tract cancer, colon cancer, rectal cancer, cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenal cancer, prostate cancer, breast cancer, brain cancer, lung cancer, anaplastic thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureter cancer, pancreatic cancer, bone / soft tissue sarcoma, skin cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia and solitary myeloma.

[0034] Since cancer has already been described in detail in the present invention, the description thereof will be omitted to avoid excessive duplication.

[0035] According to a specific embodiment of the present invention, the composition inhibits cancer growth or inhibits cancer metastasis.

[0036] As used herein, the term "cancer metastasis" refers to the tendency of cancer to spread to other locations separated by a distance from the organ or part of origin. A metastatic cancer is a cancer that has the tendency to metastasize or has metastasized. In particular, the metastatic cancer may metastasize to the liver, lungs, bones, lymph nodes, or abdominal cavity, but is not limited thereto. The metastatic cancer may be difficult to treat and may progress and be more complicated to treat than the initial treatment course.

[0037] In the present invention, the term "cancer recurrence" refers to cancer that is not found after treatment and is found again after a certain period of time has passed. Recurrent cancer refers to cancer that occurs as a result of cancer recurrence as described above. When cancer recurs, it is often difficult to remove the cancer, and even if removal is possible, a significant amount of surgery may be required. In addition, there may be limitations to anticancer treatment and radiation treatment.

[0038] According to a specific embodiment of the present invention, the Salmonella may be a Salmonella transformed with a vector containing a DNA construct including any one selected from the group consisting of a gene encoding a regulatory protein; a promoter of the gene encoding the regulatory protein; a first promoter and a second promoter induced by the regulatory protein; and a gene encoding an anti-cancer protein downstream of the first promoter and the second promoter; a gene encoding a cytokine; a gene encoding a chemokine; a gene encoding an immune modulator; an oligonucleotide specific to a cancer antigen; and a gene encoding a reporter protein.

[0039] As used herein, the term "cytokine" refers to a protein secreted by immune cells, and the cytokines of the present invention include all cytokines that can be used in cancer immunotherapy by regulating the host immune response and inducing the death of disease-related cells, such as cancer cells, and may be preferably, but are not limited to, IFN-alpha2, IL-2, IL-15, IL-21 and IL-12.

[0040] As used herein, the term "chemokine" refers to any chemokine that plays a role in regulating the movement of cells between tissues and the location and interaction of cells within tissues, and that can mediate the host response to disease, e.g., cancer, by inducing leukocytes to the tumor microenvironment. Preferably, CXCR3, CCR5, etc. may be used, but is not limited to these.

[0041] As used herein, the term "immunomodulator" refers to anything that utilizes an individual's inherent immune system to enable a variety of treatments, and can activate immune cells to induce the death of disease-related cells, such as cancer cells.

[0042] As used herein, the term "anti-cancer protein" refers to a peptide having the function of directly or indirectly inducing the death of cancer cells, and may be, for example, at least one selected from the group consisting of a toxin protein, an antibody specific to a cancer antigen or a fragment of the antibody, a tumor suppressor protein, an angiogenesis inhibitor, a cancer antigen, a prodrug-converting enzyme, a pro-apoptotic protein, and flagellin, but is not limited thereto.

[0043] The first and second promoters of the present invention can be simultaneously induced by one regulatory protein expressed by another promoter, so that the expression levels of the proteins encoded by the host cell or the genes operably linked to the first and second promoters in the host cell can be balanced compared to when a gene encoding a regulatory protein is operably linked to the downstream of the second promoter. In this way, when the DNA construct is used, diagnosis and treatment are performed simultaneously.

[0044] According to the present invention, a "DNA construct" is a structure that allows a target protein to be expressed when introduced into a host strain or cell by transformation, and includes not only a gene encoding the target protein, but also a base sequence corresponding to a promoter, which is an essential regulatory element operably linked to enable the gene to be expressed. means...

[0045] The "promoter" of the present invention refers to a base sequence present in the upstream region of a gene operably linked to a host strain or cell, and a base sequence at a specific site of the DNA construct to which RNA polymerase can bind to initiate transcription.

[0046] According to a specific embodiment of the present invention, the regulatory protein is a TetR protein, the promoter of the gene encoding the regulatory protein is an OXB1 promoter, the first promoter induced by the regulatory protein is a tetA promoter, and the second promoter induced by the regulatory protein is a tetR promoter.

[0047] According to a particular embodiment of the invention, the expression of said regulatory protein is regulated by a cis-acting or trans-acting element.

[0048] The expression of the regulatory protein of the present invention can be regulated by a cis-acting element (CRE) or a trans-acting element (TRE).

[0049] In the present invention, the term "regulation" or "regulation of expression" can mean that the transcription and translation of a specific gene is activated or inhibited.

[0050] According to a specific embodiment of the present invention, the cis-acting element may be at least one selected from the group consisting of a ribosome binding site (RBS), a 5'-untranslated region (5'-UTR), a transcription factor binding site, and a terminator, but is not limited thereto.

[0051] As used herein, the term "ribosome binding site (RBS)" is also referred to as Shine-Dalgarno sequence (SD sequence), and refers to a short sequence present on mRNA that allows ribosomes to effectively bind to the mRNA after the genetic information in DNA is transcribed into messenger RNA (mRNA) and translation occurs.

[0052] As used herein, the term "5'-Untranslated Region (5'-UTR)" refers to an untranslated region located on either side of the 5' region, which is the coding region that is translated into mRNA amino acids. This region was previously considered a junk region during evolution, but is now known to play an important role in regulating gene expression.

[0053] As used herein, the term "transcription factor binding site" refers to a DNA site that serves to turn on or off a specific gene nearby. The transcription factor binding sites are found in promoters, enhancers, and silencers of genes that code for the regulatory proteins. r), but is not limited thereto.

[0054] According to a particular embodiment of the invention, said transcription factor binding site is selected from the group consisting of: a promoter; an enhancer; and a silencer of a gene encoding said regulatory protein.

[0055] The enhancer of the present invention is a sequence found in both prokaryotes and eukaryotes, generally has a region of 50 to 1500 bp, and is located upstream or downstream from the start of the nearby gene to induce the binding of the transcription factor.

[0056] The silencer of the present invention maintains the same mechanism as the enhancer and acts as an antagonism of the enhancer. The transcription factor that binds to the silencer is a repressor. The enhancer and the silencer may be in adjacent regions, or may be in the same region but with different transcription factors.

[0057] According to a particular embodiment of the invention, the promoter of the gene encoding the regulatory protein is a weak promoter.

[0058] The promoter of the gene encoding the regulatory protein of the present invention may be any promoter whose activity can be induced under most environmental conditions and developmental states of host strains or cells, and may preferably be a weak promoter.

[0059] As used herein, the term "weak promoter" refers to a promoter that suppresses the expression level of a transcript transcribed from a gene operably linked downstream of the weak promoter by less than 1×10 -2 Less than or equal to 1×10 -3 a promoter that induces expression of 1×10 or less of the transcript as described above, -3The promoter may be at least one selected from the group consisting of, but is not limited to, any promoter that causes expression of the following: E. coli σ70 promoter; E. coli σS promoter; E. coli σ32 promoter; B. subtilis σA promoter; B. subtilis σB promoter; Salmonella-derived promoters K112706 or K112707; bacteriophage T7 promoter; bacteriophage SP6 promoter; yeast-derived promoters; eukaryotic cell-derived promoters I712004 or K076017; OXB1 promoter; and plant-derived promoters.

[0060] The E. coli σ70 promoter of the present invention is I14018, I14033, I14034, I732021, I742126, J01006, J23103, J23109, J23112, J23113, J23117, J23119, J23150, J23151, J44002, J48104, J56015, J649 51, K088007, K119000, K119001, K1330002, K137029, K137030, K137031, K137032, K137085, K137086, K137087, K137088, K137089, K137090, K137091, K1585100, K158 5101, K1585102, K1585103, K1585104, K1585105, K1585106, K1585110, K1585113, K1585115, K1585116, K1585117, K1585118, K1585119, K2486171, K256002, K25601 Consists of 8, K256020, K256033, K292000, K823007, K823010, K823013, M13101, M13102, M13103, M13104, M13105, M13106, M13108, M13110, M31519, R1074, R1075 and S03331 The compound may be at least one selected from the group listed below, but is not limited thereto.

[0061] The E. coli σS promoter of the present invention may be, but is not limited to, J45992 or J45993.

[0062] The E. coli σ32 promoter of the present invention may be, but is not limited to, J45504, K1895002 or K1895003.

[0063] The B. subtilis σA promoter of the present invention may be at least one selected from the group consisting of K143012, K143013, K823000, K823002 and K823003, but is not limited thereto.

[0064] The B. subtilis σB promoter of the present invention may be, but is not limited to, K143010, K143011 or K143013.

[0065] The bacteriophage T7 promoter of the present invention may be at least one selected from the group consisting of I719005, J34814, J64997, K113010, K113011, K113012, K1614000, R0085, R0180, R0181, R0182, R0183, Z0251, Z0252 and Z0253, but is not limited thereto.

[0066] The bacteriophage SP6 promoter of the present invention may be, but is not limited to, J64998.

[0067] The yeast-derived promoter of the present invention may be at least one selected from the group consisting of I766557, J63005, K105027, K105028, K105029, K105030, K105031, K122000, K124000, K124002, K319005, M31201, K2365040, K2365036, K2365041, K2365042, K2365032, K2365051, K2365514, K2365515 and K2365516, but is not limited thereto.

[0068] The plant-derived promoter of the present invention may be at least one selected from the group consisting of PLPR0203, PLPR0210, PLPR0177, PLPR0193, PLPR0507, PLPR0422, PLPR0228, PLPR0226, PLPR0223, PLPR0040, PLPR0465, PLPR0232, PLPR0205, PLPR0247, PLPR0328, PLPR0525, AtREG383, AtREG415, AtREG416, OsREG438, OsREG443, OsREG501, PpREG186, PpREG194 and PpREG197, but is not limited thereto.

[0069] In the present invention, the weak promoter may be, but is not limited to, the OXB1 promoter represented by SEQ ID NO:4.

[0070] For the purposes of the present invention, when a gene encoding a regulatory protein is operably linked downstream of the weak promoter, the transcription of the gene located downstream of the first and second promoters can be regulated so that it occurs specifically only when a substance that inhibits the regulatory protein is administered, compared to when the gene is operably linked downstream of the first or second promoter.

[0071] The promoter of the gene encoding the regulatory protein of the present invention may have a base sequence of SEQ ID NO: 2 at the -35 site and a base sequence of SEQ ID NO: 3 at the -10 site based on the gene encoding the regulatory protein, but is not limited thereto.

[0072] The weak promoter is a promoter that produces a transcript transcribed from a gene operably linked downstream of the promoter at an expression level of 1×10 -2 It may be the following.

[0073] According to a specific embodiment of the present invention, the trans-acting factor may be at least one selected from the group consisting of a transcription factor, an aptamer, a sRNA, and an antisense RNA (asRNA), but is not limited thereto.

[0074] In the present invention, the transcription factor is a protein that binds to the transcription factor binding site and helps to turn on and off a particular gene.

[0075] As used herein, the term "aptamer" refers to a part of a riboswitch that is an oligonucleotide or peptide substance capable of binding to a specific target molecule, and the aptamer may be a peptide aptamer or a nucleic acid aptamer. The riboswitch is a type of mRNA that regulates gene expression, and includes, but is not limited to, glmS riboswitch, FMN riboswitch, and Cobalamin riboswitch.

[0076] In the present invention, the sRNA or antisense RNA (asRNA) refers to a single-stranded RNA that can bind complementarily to a specific RNA. It binds complementarily to sense RNA, which is messenger RNA (mRNA) that expresses a specific protein, and ultimately regulates the expression of the protein.

[0077] According to a specific embodiment of the present invention, the anti-cancer protein is selected from the group consisting of a toxin protein, an antibody or a fragment of said antibody specific to a cancer antigen, a tumor suppressor protein, an angiogenesis inhibitor, a cancer antigen, a prodrug-converting enzyme, and a pro-apoptotic protein.

[0078] As used herein, the term "tumor suppressor protein" refers to a gene that maintains its function while present in normal cells, but when its function is lost, induces indiscriminate cell division and growth in normal cells, transforming them into cancer cells. Examples of such a gene include, but are not limited to, RB (Retinoblastoma protein) protein, p53 protein, APC (Adenomatous polyposis coli) protein, PTEN (Phosphatase and tensin homologue) protein, and CDKN2A (cyclin dependent kinase inhibitor 2A) protein.

[0079] The antibody or antibody fragment specific to the cancer antigen of the present invention is an antibody that can specifically bind to an antigen that is a protein that is specifically expressed at a high level on the surface or cytoplasm of cancer cells, and may be, for example, an antibody specific to HER2, which is specifically expressed at a high level in breast cancer or gastric cancer cells, but is not limited thereto.

[0080] The antibody of the present invention means a protein molecule capable of specifically binding to an antigenic site of a protein or peptide molecule. The form of the antibody is not particularly limited, and includes all types of immunoglobulin antibodies, including polyclonal antibodies, monoclonal antibodies, and antibodies that have antigen-binding properties, even if they are a part of an antibody. In addition, special antibodies such as humanized antibodies are included, and the antibody includes not only a complete form having two full-length light chains and two full-length heavy chains, but also a functional fragment of an antibody molecule. The functional fragment of an antibody molecule means a fragment that has at least an antigen-binding function, and may be, but is not limited to, Fab, F(ab'), F(ab')2, Fv, etc.

[0081] The "antibody" of the present invention is produced by a conventional method after cloning the gene encoding the cancer antigen of the present invention into an expression vector by a conventional method to obtain the protein encoded by the gene.

[0082] As used herein, the term "angiogenesis inhibitor" refers to a protein or compound that has the function of directly or indirectly inducing the death of cancer cells by inhibiting the generation of new blood vessels around cancer cells. Preferably, the angiogenesis inhibitor may be, but is not limited to, angiostatin, endostatin, thrombospondin, and protease inhibitor protein.

[0083] As used herein, the term "cancer antigen" refers to a protein that is expressed in cancer cells but is rarely expressed in normal cells, and that can induce an antitumor immune response and thereby induce direct or indirect death of cancer cells. The cancer antigen of the present invention is preferably alpha-fetoprotein (AFP), vascular endothelial growth factor receptor 2 (VAG2R2), or the like. The antigen may be, but is not limited to, prostate cancer specific antigen (PCSA), growth factor receptor 2 (VEGFR2), survivin, legumain, or the like.

[0084] According to a specific embodiment of the invention, the toxin protein is selected from the group consisting of ricin, saporin, gelonin, momordin, devouganin, diphtheria toxin, Pseudomonas toxin, hemolysin (HlyA), FAS ligand (FASL), tumor necrosis factor-α (TNF-α), TNF-related apoptosis-inducing ligand (TRAIL) and cytolysin A (ClyA).

[0085] As used herein, the term "toxic protein" refers to a protein having a function of directly or indirectly inducing the death of cancer cells, such as ricin, saporin, gelonin, momordin, debouganin, diphtheria toxin, Pseudomonas aeruginosa toxin, and the like. It may be at least one selected from the group consisting of amino acid sequence represented by SEQ ID NO: 1, and more preferably, the amino acid sequence represented by SEQ ID NO: 1. The nucleic acid may be, but is not limited to, cytolysin A consisting of the sequence.

[0086] According to a specific embodiment of the present invention, the tumor suppressor protein is selected from the group consisting of RB (Retinoblastoma protein) protein, p53 protein, APC (Adenomatous polyposis coli) protein, PTEN (Phosphatase and tensin homologue) protein, and CDKN2A (cyclin dependent kinase inhibitor 2A) protein.

[0087] In the present invention, the tumor suppressor protein has already been described in detail, so the description thereof will be omitted to avoid excessive duplication.

[0088] According to a specific embodiment of the invention, the angiogenesis inhibitor is selected from the group consisting of angiostatin, endostatin, thrombospondin and protease inhibitor protein.

[0089] In the present invention, the angiogenesis inhibitor has already been described in detail, so the description thereof will be omitted to avoid excessive duplication.

[0090] According to yet another aspect of the invention, the invention provides a method of preventing or treating cancer by administering to an individual a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor.

[0091] According to yet another aspect of the present invention there is provided the use of a Salmonella strain and an immune checkpoint inhibitor for preventing or treating cancer. Effect of the Invention

[0092] The features and advantages of the present invention can be summarized as follows: (a) The present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients. (b) The present invention can be useful as a preventive or therapeutic composition for cancer, particularly cancers that are resistant or difficult to treat with a single anticancer therapy, by administering bacteria in combination with an immune checkpoint inhibitor to significantly suppress tumor size and thereby improve survival rates. [Brief description of the drawings]

[0093] [Figure 1A] 1 shows an experimental timeline for combination therapy of Salmonella with immune checkpoint inhibitors according to one embodiment of the present invention. [Figure 1B] 1 is a graph showing the anti-cancer effect as measured by changes in tumor size when Salmonella and an immune checkpoint inhibitor are administered in combination, according to an example of the present invention. [Figure 1C] 1 shows the results of an experimental example of the present invention showing the survival rate when Salmonella and an immune checkpoint inhibitor are administered in combination. [Figure 1D] 1 shows the results of changes in tumor size when tumors were re-implanted into mice that had been removed by combination therapy according to an example of the present invention. [Figure 2A] 1 shows an experimental schedule for transplanting a tumor again after transplantation of a CT26 cell tumor according to an experimental example of the present invention. [Figure 2B] 1 is a graph showing the change in tumor size when tumors were re-implanted into mice that had been removed by combination therapy according to an example of the present invention. [Figure 3A] According to an example of the present invention, this is a graph showing the change in tumor size after MC38 cell tumor transplantation and injection of IgG, Anti-PD-L1, CNC018+IgG, and CNC018+anti-PD-L1. [Figure 3B] 1 is a graph showing the survival rates of mice injected with IgG, Anti-PD-L1, CNC018+IgG, and CNC018+anti-PD-L1 after transplantation of MC38 cell tumors in accordance with an example of the present invention. [Figure 4A] According to an example of the present invention, this is a graph showing the change in tumor size after MC38 cell tumor transplantation and injection of IgG, Anti-PD-L1, SL△ppGpp+IgG, and SL△ppGpp+anti-PD-L1. [Figure 4B] 1 is a graph showing the survival rate after injecting IgG, Anti-PD-L1, SL△ppGpp+IgG, and SL△ppGpp+anti-PD-L1, respectively, after transplantation of MC38 cell tumors in accordance with an experimental example of the present invention. [Figure 5A] 1 shows an experimental schedule for transplanting a tumor again after transplantation of an MC38 cell tumor according to an example of the present invention. [Figure 5B] 1 is a graph showing the change in tumor size when a MC38 cell tumor was transplanted into mice pretreated with CNC018 and SLΔppGpp according to an example of the present invention, and then the tumor was transplanted again into the mice. [Figure 6A] 1 shows the results of an experiment of the present invention showing the change in size of mouse spleen when combined therapy is performed after tumor transplantation. [Figure 6B] 1 shows the results of changes in mouse spleen weight when combination therapy was performed after tumor transplantation according to an example of the present invention. [Figure 7A] 1 shows the results of an experimental example of the present invention showing activation of memory CD8+ T cells by combination therapy after tumor transplantation. [Figure 7B] 1 shows the results of an experimental example of the present invention showing activation of memory CD4+memory T cells by combination therapy after tumor transplantation. [Figure 8A] 1 shows results showing activation of IFN-γ-specific CD4+ T cells by combination therapy according to an experimental example of the present invention. [Figure 8B] 1 shows results showing activation of IFN-γ-specific CD8+ T cells by combination therapy according to an experimental example of the present invention. [Figure 9A] 1 shows the results of confirming the inhibitory effect of combination therapy on cancer metastasis to the lungs in one experimental example of the present invention. [Figure 9B]1 shows a graph showing the effect of suppressing cancer metastasis to the lungs by combination therapy according to one experimental example of the present invention. [Figure 10A] 1 shows the results of an experiment of the present invention, confirming the effect of combination therapy in suppressing cancer metastasis to the liver in mice. [Figure 10B] 1 is a graph showing the results of confirming the inhibitory effect of combination therapy on cancer metastasis to the liver in mice according to one experimental example of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0094] The present invention relates to a reliable composition for preventing and treating cancers that are difficult to treat with resistance and single anticancer therapy and have no effective treatment methods. The present invention develops a composition for preventing or treating cancers using a Salmonella strain and an immune checkpoint inhibitor as active ingredients, and confirms that tumor growth is significantly suppressed and improved by combination therapy of a Salmonella strain that selectively acts on cancer and an immune checkpoint inhibitor including PD-L1, thereby providing a fundamental and efficient method and composition for treating cancer. EXAMPLES

[0095] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention in more detail, and that the scope of the present invention is not limited to these examples according to the gist of the present invention.

[0096] Working Example [Preparation Example 1] Cancer cell lines and culture conditions CT26 colon cancer cell lines, CRL-2638 and HB-8064 (ATCC, USA) and mouse colon adenocarcinoma cell line, MC38 (Massachusetts General Hospital and Harvard Medical School, USA and Chonnam National University, Korea) were used in the experiments.

[0097] The cells were cultured in a high glucose Dulbecco's Modified Eagles Medium (DMEM) medium (catalog number: #LM001-05, Welgene, Korea) containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin at 37°C in a 5% CO2 incubator.

[0098] [Preparation Example 2] Preparation of Salmonella strains carrying plasmids The Salmonella strains used were ppGpp-deficient Salmonella typhimurium (S. typhimurium), SL△ppGpp (ΔrelA, ΔspoT) and CNC018 (ΔrelA, ΔspoT, ΔSPI1, ΔSPI2).

[0099] The plasmids prepared in the Salmonella strains were transformed by electroporation, and the transformed strains were cultured overnight in LB medium containing 100 μg / ml ampicillin. The cultures were then diluted 1:100 with fresh LB medium containing ampicillin and cultured in a shaking incubator at 200 rpm and 37°C. The cultures were centrifuged to obtain strain pellets, which were washed with PBS buffer and then used in the experiments.

[0100] [Preparation Example 3] Preparation of experimental animal model C57BL / 6 and BALB / C mice (Orient Company, Korea) aged 5 to 6 weeks and weighing 20 to 30 g were used. MC38 or CT26 of Preparation Example 1 was subcutaneously injected into the flank of the mice to establish a tumor animal model.

[0101] For imaging of the tumor animal models and evaluation of tumor size, 2% isoflurane was used for anesthesia, and 200 mg / kg ketamine and 10 mg / kg xylasine were used during surgery.

[0102] The size of the tumor (mm 3 The evaluation of the tumor size was calculated using (length × height × width) / 2, and the tumor size of the animal model was 1500 mm 3 In these cases, the animal model was euthanized.

[0103] [Experimental Example 1] Confirmation of anti-cancer effect by combined administration of Salmonella strain and immune checkpoint inhibitor (1) To confirm the anti-cancer effect of the combination of Salmonella strains and the immune checkpoint inhibitor anti-PD-L1, an in vivo experiment was performed as shown in Figure 1A. After injecting each drug into a CT26 tumor mouse model, the bacterial strain was intravenously injected on the 10th day.

[0104] After injection of PBS, anti-PD-L1, CNC018-IgG, CNC018-anti-PD-L1-anti-CALR, and CNC018-anti-PD-L1, changes in tumor size could be observed (Figure 1B).

[0105] When the attenuated Salmonella strain and anti-PD-L1 were administered in combination, the tumor size was significantly improved compared to the PBS control group, and the survival rate of the mice was also significantly improved (Figure 1C). In addition, as shown in Figure 1D, the tumor was re-implanted on day 91 into mice that had had their tumors removed by combination therapy, and the change in tumor size was examined. The change in tumor size was confirmed to be very small compared to the control group (naive mice), confirming that CNC018-anti-PD-L1 is also effective against tumor recurrence.

[0106] [Experimental Example 2] Confirmation of anti-cancer effect by combined administration of Salmonella strain and immune checkpoint inhibitor (2) To confirm the anti-cancer effect of the combination of Salmonella strain and the immune checkpoint inhibitor anti-PD-L1, and in particular to confirm the effect of suppressing cancer recurrence when tumors were re-implanted into mice that had had their tumors removed by combination therapy, in vivo experiments were performed using the experimental method shown in Figure 2A to confirm the growth-suppressing effect of SL△ppGpp-anti-PD-L1 and CNC018-anti-PD-L1 in the tumor on the CT26 cell line. Attenuated Salmonella strains were inoculated into the CT26 mouse model at 1×10 7 An experiment was performed in which the mice were intravenously administered CFU in the control group, and the tumor size is shown in Figure 2B.

[0107] As shown in Figure 2B, when SL△ppGpp-anti-PD-L1 and CNC018-anti-PD-L1 were pretreated, the tumor suppression ability was significantly increased compared to the control group, confirming the anti-cancer and recurrence suppression effects of SL△ppGpp-anti-PD-L1 and CNC018-anti-PD-L1.

[0108] [Experimental Example 3] Confirmation of anti-cancer effect by combined administration of Salmonella strain and immune checkpoint inhibitor (3) To confirm the anti-cancer effect of the combination of Salmonella strains and the immune checkpoint inhibitor anti-PD-L1, in vivo experiments were performed to measure tumor size and mouse survival rates after injecting IgG, anti-PD-L1, CNC018-IgG, and CNC018-anti-PD-L1 into MC38 tumors. The results showed that mice co-administered with CNC018-anti-PD-L1 had significantly higher tumor suppression ability than the control IgG, and thus the survival rates of mice were also significantly increased (Figures 3A and 3B).

[0109] Figure 3A: Six mice per group were used in the experiment, two-way ANOVA with Tukey's multiple comparisons test was used (****P<0.0001). Figure 3B: Six mice per group were used in the experiment, Kaplan-Meier survival curves for MC38-tumor bearing mice were used (**P=0.0016 (CNC018+anti-PD-L1 vs IgG or CNC018+IgG;**P=0.0033, CNC018+anti-PD-L1 vs Anti-PD-L1)log-rank(Mantel-Cox test)).

[0110] [Experimental Example 4] Confirmation of anti-cancer effect by combined administration of Salmonella strain and immune checkpoint inhibitor (4) To confirm the anti-cancer effect of the combination of Salmonella strains and the immune checkpoint inhibitor anti-PD-L1, in vivo experiments were performed to measure tumor size and mouse survival rate after injecting IgG, anti-PD-L1, SLβ-IgG, and SLβ-anti-PD-L1 into MC38 tumors. The results showed that the tumor suppression ability of mice administered SLβ-anti-PD-L1 in combination was significantly higher than that of the control IgG, and the mouse survival rate was also very high (Figures 4A and 4B).

[0111] Figure 4A shows two-way ANOVA with Tukey's multiple comparisons test, 6 mice per group (***P=0.0002, ****P<0.0001). Figure 4B shows Kaplan-Meier survival curves for MC38-tumor bearing mice, 6 mice per group (**P=0.0016 (CNC018+anti-PD-L1 vs IgG or CNC018+IgG; **P=0.0084, CNC018+anti-PD-L1 vs Anti-PD-L1), *P=0.0432 log-rank (Mantel-Cox test)).

[0112] [Experimental Example 5] Confirmation of anti-cancer effect of Salmonella strains To confirm the anti-cancer effect of the Salmonella strain, and in particular to confirm the effect of suppressing cancer recurrence when tumors were re-implanted into mice from which tumors had been removed, in vivo experiments were performed using the experimental method in Figure 5A to confirm the growth-suppressing effect of intratumoral SLβ and CNC018-anti-PD-L1 on the MC38 cell line. Attenuated Salmonella strains were inoculated into the MC38 mouse model at a concentration of 1 × 10 7 An experiment was performed in which the mice were intravenously administered CFU, whereas a control group was not administered the drug, and the tumor size is shown in FIG. 5B.

[0113] As shown in Figure 5B, when SLβ and CNC018 were pretreated, the tumor-suppressing ability was significantly increased compared to the control group of native mice, confirming the anti-cancer and recurrence-suppressing effects of SLβ and CNC018-anti-PD-L1.

[0114] [Experimental Example 6] Confirmation of changes in the spleen after combined administration of Salmonella strain and immune checkpoint inhibitor To confirm the changes in the spleen caused by the combination of Salmonella strains and the immune checkpoint inhibitor anti-PD-L1, we examined the changes in the size and weight of the mouse spleen after injection of PBS, CNC018-IgG, and CNC018-anti-PD-L1 (Figure 6). CNC018-anti-PD-L1-anti-CD4, CNC018-anti-PD-L1-anti-CD8, and CNC018-anti-PD-L1-anti-CD4-anti-CD8 were used as negative controls.

[0115] As shown in Figure 6, when used in combination therapy with CNC018-anti-PD-L1, biostability was confirmed by observing minimal changes in spleen size and weight.

[0116] [Experimental Example 7] Confirmation of activation of tumor-specific memory T cells by combined administration of Salmonella strains and immune checkpoint inhibitors (1) To confirm the activation of T cells by the combined administration of Salmonella strains and the immune checkpoint inhibitor anti-PD-L1, PBS, CNC018-IgG, and CNC018-anti-PD-L1 were injected, and the activation of tumor-specific memory T cells was confirmed. The results of the experiment showed that the effector memory CD4 + T cells and effector memory CD8 + A significant increase was observed in the group administered in combination with T cells (FIGS. 7A and 7B).

[0117] [Experimental Example 8] Confirmation of activation of tumor-specific memory T cells by combined administration of Salmonella strains and immune checkpoint inhibitors (2) Salmonella strains were administered in combination with the immune checkpoint inhibitor anti-PD-L1. To confirm the activation of T cells, we injected PBS, CNC018-IgG, and CNC018-anti-PD-L1, and then confirmed the activation of tumor-specific memory T cells. 5 spleen cells and 2.5 x 10 5 The cells were co-cultured with irradiated CT26 cancer cells for 12 hours. After stimulation, Golgiplug (1 μl / ml) containing brefeldin A was added to block intracellular protein transport processes for 5 hours. Intracellular staining of interferon-gamma (IFNγ) was performed by FACS analysis.

[0118] As shown in Figures 8A and 8B, IFNγ was significantly increased compared to the control PBS. + CD4 + T cells, and IFNγ + CD8 + A significant increase was observed in the group administered with T cells in combination.

[0119] [Experimental Example 9] Confirmation of the effect of combined administration of Salmonella strain and immune checkpoint inhibitor on suppressing cancer metastasis (1) To confirm the effect of combining Salmonella strains with the immune checkpoint inhibitor anti-PD-L1 on suppressing cancer metastasis, IgG, anti-PD-L1, CNC018-anti-PD-L1 isotype, CNC018-anti-PD-L1, and CNC018-anti-PD-L1 isotype-anti-CSF1R were injected, and metastatic nodules were identified in the lungs (Figure 9).

[0120] As shown in Figure 9B, the CNC018-anti-PD-L1 combination group showed less tumor metastasis to the lungs compared to the control IgG group, demonstrating that the combination treatment had a significantly significant effect in inhibiting tumor metastasis.

[0121] [Experimental Example 10] Confirmation of the effect of suppressing cancer metastasis by combined administration of Salmonella strain and immune checkpoint inhibitor (2) To confirm the effect of combined administration of Salmonella strains and the immune checkpoint inhibitor anti-PD-L1 on suppressing cancer metastasis, in vivo experiments were conducted to confirm the growth-suppressing effect of combined administration within the tumor on the HepG2-Luc cell line.

[0122] A HepG2-Luc cell line expressing luciferase was prepared, and a mouse model was prepared by injecting the HepG2-Luc cell line. IgG, CNC018-IgG, CNC018-anti-PD-L1, CNC018-anti-Asialo, and CNC018 were then administered, and the location of the tumor was photographed (Figure 10A). The total flux metastasized to the liver was confirmed, and it was confirmed that the group administered CNC018-anti-PD-L1 had a significant inhibitory effect compared to the control group IgG (Figure 10B).

[0123] As shown in Figure 10, when CNC018-anti-PD-L1 was administered in combination, the tumor did not metastasize to the liver compared to the control group, demonstrating that the combined administration of CNC018 and anti-PD-L1 had a significant effect in inhibiting tumor metastasis.

[0124] Although certain parts of the present invention have been described in detail above, it is obvious to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0125] Sequence Listing Free Text [Table 1] [Industrial Applicability]

[0126] The present invention relates to a reliable composition for preventing and treating cancers that are difficult to treat with resistance and single anticancer therapy and have no effective treatment method. Currently, patients who respond effectively to immune checkpoint inhibitors in cancer treatment vary depending on the cancer, and the effect is also limited, so there is a need for a new therapeutic composition. The present invention develops a composition for preventing or treating cancer using a Salmonella strain and an immune checkpoint inhibitor as active ingredients, and confirms that tumor growth is significantly suppressed and improved by combination therapy of a Salmonella strain that selectively acts on cancer and an immune checkpoint inhibitor including PD-L1, and is expected to be used to provide a fundamental and efficient method and composition for treating cancer.

Claims

1. A pharmaceutical composition for preventing or treating cancer, comprising a Salmonella strain and an immune checkpoint inhibitor as active ingredients.

2. The pharmaceutical composition of claim 1 , wherein the composition is administered in combination.

3. 2. The pharmaceutical composition of claim 1, wherein the Salmonella strain comprises one or more selected from the group consisting of Salmonella typhimurium, Salmonella choleraesuis, Salmonella enteritidis, Salmonella dublin, Salmonella typhisuis, Salmonella derby, and Salmonella gallinarum.

4. The pharmaceutical composition according to claim 3, wherein the Salmonella strain is Salmonella typhimurium.

5. The pharmaceutical composition according to claim 1, wherein the immune checkpoint inhibitor comprises at least one selected from the group consisting of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), KIR, LAG3, CD137, OX40, CD47, CD276, CD27, and GITR.

6. The pharmaceutical composition according to claim 5, wherein the immune checkpoint inhibitor is programmed death-ligand 1 (PD-L1).

7. 2. The pharmaceutical composition of claim 1, wherein the cancer comprises one or more selected from the group consisting of melanoma, fallopian tube cancer, brain cancer, small intestine cancer, esophageal cancer, lymphatic gland cancer, gallbladder cancer, blood cancer, thyroid cancer, endocrine gland cancer, oral cancer, liver cancer, biliary tract cancer, colon cancer, rectal cancer, cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenal cancer, prostate cancer, breast cancer, brain cancer, lung cancer, anaplastic thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureter cancer, pancreatic cancer, bone / soft tissue sarcoma, skin cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and solitary myeloma.

8. The pharmaceutical composition according to claim 1 , wherein the composition inhibits cancer growth or cancer metastasis.

9. The Salmonella is genes encoding regulatory proteins; a promoter of a gene encoding said regulatory protein; a first promoter and a second promoter induced by the regulatory protein; and A gene encoding an anti-cancer protein downstream of the first promoter and the second promoter is selected from the group consisting of a gene encoding a cytokine; a gene encoding a chemokine; a gene encoding an immune modulator; an oligonucleotide specific to a cancer antigen; and a gene encoding a reporter protein. The pharmaceutical composition of claim 1, which is a Salmonella transformed with a vector containing a DNA construct comprising any one of the above.

10. the regulatory protein is a TetR protein, the promoter of the gene encoding the regulatory protein is the OXB1 promoter; the first promoter induced by the regulatory protein is the tetA promoter; 10. The pharmaceutical composition of claim 9, wherein the second promoter induced by the regulatory protein is a tetR promoter.

11. 2. The pharmaceutical composition of claim 1, which is a Salmonella comprising a DNA construct in which the expression of the regulatory protein is regulated by a cis-acting element or a trans-acting element.

12. The pharmaceutical composition according to claim 11, wherein the cis-acting factor is a Salmonella comprising a DNA construct which is at least one selected from the group consisting of a ribosome binding site (RBS), a 5'-untranslated region (5'-UTR), a transcription factor binding site, and a terminator.

13. The pharmaceutical composition of claim 12, wherein the transcription factor binding site is at least one selected from the group consisting of a promoter of a gene encoding the regulatory protein; an enhancer; and a silencer.

14. The pharmaceutical composition of claim 13, wherein the promoter of the gene encoding the regulatory protein is a weak promoter.

15. The weak promoter is a promoter that can express a transcript transcribed from a gene operably linked downstream of the promoter at an expression level of 1×10 -2 15. The pharmaceutical composition of claim 14, which is a Salmonella comprising a DNA construct:

16. The pharmaceutical composition according to claim 11, wherein the trans-acting factor is a Salmonella containing DNA construct that is at least one selected from the group consisting of a transcription factor, an aptamer, a sRNA, and an antisense RNA (asRNA).

17. 10. The pharmaceutical composition of claim 9, wherein the anti-cancer protein is a Salmonella containing a DNA construct that is at least one selected from the group consisting of a toxin protein, an antibody or a fragment of the antibody specific to a cancer antigen, a tumor suppressor protein, an angiogenesis inhibitor, a cancer antigen, a prodrug-converting enzyme, and a pro-apoptotic protein.

18. The toxic proteins include ricin, saporin, gelonin, momordin, and debouganin. aeruginosa toxin, diphtheria toxin, Pseudomonas toxin, hemolysin (HlyA), FAS ligand (FASL), tumor necrosis factor-α (TNF-α), TNF-related apoptosis-inducing ligand (TRAIL), and cytolysin A (ClyA).

19. The tumor suppressor protein includes RB (Retinoblastoma protein), p53 protein, APC (Adenomatous polyposis The pharmaceutical composition according to claim 17, which is a Salmonella comprising a DNA construct comprising at least one selected from the group consisting of E. coli protein, PTEN (phosphatase and tensin homologue) protein, and CDKN2A (cyclin dependent kinase inhibitor 2A) protein.

20. The pharmaceutical composition of claim 17, wherein the angiogenesis inhibitor is a Salmonella containing DNA construct that is at least one selected from the group consisting of angiostatin, endostatin, thrombospondin, and protease inhibitor protein.

21. A method of preventing or treating cancer by administering to an individual a pharmaceutical composition comprising a Salmonella strain and an immune checkpoint inhibitor.

22. Use of a Salmonella strain and an immune checkpoint inhibitor to prevent or treat cancer.

Citation Information

Patent Citations

  • VEGFR-2 targeted DNA vaccine for combination therapy

    JP2018517419A

  • WT1-targeting DNA vaccine for combination therapy

    JP2019533698A

  • Neoantigen targeting DNA vaccine for combination therapy

    WO2020049036A1

  • DNA construct for diagnosing and treating cancer

    WO2020231137A1